The second human trial for Ad5-nCoV is being performed in Wuhan, China with primary outcomes in determining specific and neutralizing antibody responses and adverse reaction occurrences in subjects to determine the efficacy and safety of the vaccine. Another purpose of this trial was to further narrow down an appropriate dose for the vaccine candidate.